In UAB's Division of Neurosurgery, Corinne E. Griguer, PhD and her research team is searching for potential therapeutic targets in malignant glioma. A recent recipient of a Research Project Grant, her research interests include exploring the bioenergetic pathways involved in the development and progression of malignant glioma. Patient chemoresistance to temozolomide (TMZ), the frontline drug of choice to treat glioblastoma multiforme, limits treatment options. Griguer and her colleagues at the Southern Research Institute and University of Geneva have determined that increased cytochrome c oxidase (CcO) activity is associated with TMZ resistance in glioblastoma multiforme. In the future, analysis of CcO activity in gliomas may be used to predict overall survival and progression free survivals in patients with malignant glioma. CcO activity may serve as a target for small molecule inhibitiors that could be used to block acquisition of chemoresistance in glioma. Reversing TMZ insensitivity may lead to improved outcomes in patients with GBM.
Cytochrome c Oxidase in Glioma: A Potential Marker and Therapeutic Target